Development and surveillance of hepatocellular carcinoma in patients with sustained virologic response after antiviral therapy for chronic hepatitis C
Clinical and Molecular Hepatology
;
: 234-244, 2019.
Article
in English
| WPRIM
| ID: wpr-763404
ABSTRACT
Hepatitis C virus (HCV) infection is a major risk factor for liver cirrhosis and hepatocellular carcinoma (HCC), and is a leading cause of liver-related deaths worldwide. Recently available direct-acting antiviral agent is very safe and highly effective (>95% sustained virologic response, SVR) against all genotypes of HCV. Achievement of SVR has been associated with a significant reduction of hepatic decompensation, development of HCC, and liver-related mortality. However, HCC risk is not eliminated even after SVR. The annual incidences of HCC in advanced fibrosis or cirrhosis have been estimated to be up to 2.5–4.5% even in patients with SVR. Therefore, surveillance for HCC is recommended in this high-risk patients. In this review, we will describe the clinical outcomes and the risk of HCC in patients with SVR and suggest who should receive surveillance for HCC.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Fibrosis
/
Incidence
/
Risk Factors
/
Mortality
/
Hepacivirus
/
Carcinoma, Hepatocellular
/
Hepatitis C, Chronic
/
Genotype
/
Hepatitis, Chronic
/
Liver Cirrhosis
Type of study:
Etiology study
/
Incidence study
/
Prognostic study
/
Risk factors
/
Screening study
Limits:
Humans
Language:
English
Journal:
Clinical and Molecular Hepatology
Year:
2019
Type:
Article
Similar
MEDLINE
...
LILACS
LIS